Sun Pharma Advanced Research Co Ltd
SPARCSun Pharma Advanced Research Co Ltd
SPARC
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -16.47 | 53.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 249.66 | 105.02 | 72.48 | |||
Raw Materials | 0.00 | 0.00 | 464.81 | |||
| Power & Fuel Cost | 5.75 | 6.14 | ||||
| Employee Cost | 107.00 | 141.84 | ||||
| Selling & Administrative Expenses | 289.71 | 267.06 | ||||
| Operating & Other expenses | 50.38 | 62.60 | ||||
EBITDA | -203.18 | -372.62 | -392.33 | |||
| Depreciation/Amortization | 11.77 | 12.51 | 12.53 | |||
| PBIT | -214.95 | -385.13 | -404.86 | |||
| Interest & Other Items | 7.63 | 1.69 | 2.87 | |||
| PBT | -222.58 | -386.82 | -407.73 | |||
| Taxes & Other Items | 0.00 | 0.38 | 0.94 | |||
| Net Income | -222.58 | -387.20 | -408.67 | |||
| EPS | -6.86 | -11.93 | -12.59 | |||
| DPS | 0.00 | 0.00 | 0.00 | |||
| Payout ratio | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sun Pharma Advanced Research Co Ltd | -17.39 | 53.53 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare SPARC with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Sun Pharma Advanced Research Co Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Nifty Smallcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0291% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/291 (-1) |
SBI Nifty Smallcap 250 Index Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0179% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 139/291 (-4) |
Motilal Oswal Nifty Smallcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0128% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 105/292 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SPARC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Total expenses rose 3.43% YoY to Rs 120.07 crore in September 2024 quarter. Employee benefit expenses was Rs 38.48 crore (up 25.3% YoY), professional charges stood at Rs 30.75 crore (down 26.58% YoY), clinical trial expenses at Rs 25.53 crore (up 40.2% YoY). Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.Powered by Capital Market - Live
Net Loss of Sun Pharma Advanced Research Company reported to Rs 107.33 crore in the quarter ended September 2024 as against net loss of Rs 86.42 crore during the previous quarter ended September 2023. Sales declined 39.28% to Rs 12.86 crore in the quarter ended September 2024 as against Rs 21.18 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.8621.18 -39 OPM %-800.23-431.87 - PBDT-104.01-83.24 -25 PBT-107.17-86.42 -24 NP-107.33-86.42 -24 Powered by Capital Market - Live
Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 4 November 2024Powered by Capital Market - Live
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 95.90 crore in the June 2024 quarter
Net Loss of Sun Pharma Advanced Research Company reported to Rs 95.90 crore in the quarter ended June 2024 as against net loss of Rs 95.35 crore during the previous quarter ended June 2023. Sales declined 29.81% to Rs 16.81 crore in the quarter ended June 2024 as against Rs 23.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.8123.95 -30 OPM %-555.38-426.64 - PBDT-92.36-92.25 0 PBT-95.50-95.35 0 NP-95.90-95.35 -1 Powered by Capital Market - Live
Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live
Sun Pharma Advanced Research loss widens to Rs 81.99 cr in March quarter
Sun Pharma Advanced Research Company falls 5% as quarterly loss widens to Rs 82 crore
Sun Pharma may incur revenue loss for ransomware incident on March 2
SPARC reports IT security incident, ransomware group claims responsibility
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged